Deprecated: Required parameter $cat_id follows optional parameter $type in /www/wwwroot/ebimall.com/systems/hong.php on line 2088

Deprecated: Required parameter $where follows optional parameter $tree_id in /www/wwwroot/ebimall.com/systems/hlb.php on line 3505
Ancell/anti-CD28/120 tests/177-040188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

Ancell/anti-CD28/120 tests/177-040

Human CD28 is an important costimulatory molecule found on all CD4+ T cells and on about half of the CD8+ T cells. T cell activities attributed to CD28 include prevention of anergy, induction of cytokine gene transcription, stabilization of cytokine mRNA and activation of CD8+ cytotoxic T lymphocytes. the ligands for CD28 identified as CD80(B7-1) and CD86(B7-2), are immunglobulin superfamily monomeric transmembrane glycoproteins of 60 kd and 80 kd respectively. Anti-CD28 antibodies have been shown to have a strong adjuvant effect when conjugated to an immunogen (4). Monovalency of the CD28 receptor for its natural ligands is essential to provide costimulation without inducing responses in the absense of TCR engagement (7).

Isotype: Murine IgG1kappa

Immunogen: Recombinant Human CD28 and HPB-MLT human tumor cells

Specificity: Antibody ANC28.1 recognizes CD28 expressed on T cells and also on BHK cells transfected with human CD28. This antibody has been characterized as a superagonist (5)

Functional Application: ANC28.1 stimulates expression of IL-2 from CD28+ cells. Divalent ANC28.1 can induce Antigen Independent T cell proliferation (5). the F(ab‘)2 form of this antibody is fully mitogenic (8). In combination with anti-CD81 mAb, it can prime naive T cells to acquire effector function independently (6) or in combination(9) with TCR ligation. This antibody recognizes an epitope resistant to fixation with 2% buffered formaldehyde. This clone is not suitable for Western Blot.

References:

1)M.K. Jenkins & J.G. Johnson, (1993) Curr Opin Immunol 5: 361-367.

2) 61st Forum in Immunology, (1995) Res Immunol 146: 127-205.

3) I. Kariv, A. Truneh & R.W. Sweet, (1996) J Immunol 157: 29-38.

4) J. Carlring, et al, (2003) Eur J Immunol 33: 135-142.

5) Waibler1 Z., B. Schraven, et al, (2008) PLoS ONE 3(3): e1708

6) A Serra, A Wack, et al.(2008) J Immunol 181:174-185.

7) K M Dennehy, T Hunig, et al, (2006) J Immunol 176: 5725-5729.

8) Singh M, Lewis DE, et al. (2008) 38(6): 1522-32. PMID: 18446791.

9) N Frankish, B McHale, H Sheridan (Jan 2018) J Pharm Pharmacol 70(1): 101-110. https://doi.org/10.1111/jphp.12846 PMID: 29057517

新闻动态
行业前沿
技术文章
最新产品